M D Anderson Cancer Center [clinicaltrials_resource:c3b39bc43c0411fc92a031d9d271ce71]
Gene Therapy in Treating Patients With Advanced Bladder Cancer [clinicaltrials:NCT00003167]Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease [clinicaltrials:NCT00003210]Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer [clinicaltrials:NCT00004032]PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome [clinicaltrials:NCT00005064]SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer [clinicaltrials:NCT00005818]Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery [clinicaltrials:NCT00005838]Tipifarnib in Treating Patients With Myelodysplastic Syndromes [clinicaltrials:NCT00005845]Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy [clinicaltrials:NCT00005942]506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma [clinicaltrials:NCT00005950]BMS-214662 in Treating Patients With Solid Tumors [clinicaltrials:NCT00005973]506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma [clinicaltrials:NCT00005982]Celecoxib in Treating Patients With Bladder Cancer [clinicaltrials:NCT00006124]BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia [clinicaltrials:NCT00006213]Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia [clinicaltrials:NCT00006364]Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [clinicaltrials:NCT00006473]SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment [clinicaltrials:NCT00009919]Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer [clinicaltrials:NCT00016289]Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia [clinicaltrials:NCT00023920]SU6668 in Treating Patients With Advanced Solid Tumors [clinicaltrials:NCT00024206]PS-341 in Treating Women With Metastatic Breast Cancer [clinicaltrials:NCT00025584]Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer [clinicaltrials:NCT00033358]clinicaltrials:NCT00033371UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer [clinicaltrials:NCT00039403]Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer [clinicaltrials:NCT00041340]Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer [clinicaltrials:NCT00045188]Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed [clinicaltrials:NCT00047333]Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction [clinicaltrials:NCT00047346]Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia [clinicaltrials:NCT00054431]clinicaltrials:NCT00054639Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors [clinicaltrials:NCT00055809]Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction [clinicaltrials:NCT00061958]clinicaltrials:NCT00063934Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx [clinicaltrials:NCT00064103]Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme [clinicaltrials:NCT00075491]CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer [clinicaltrials:NCT00075647]Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma [clinicaltrials:NCT00082875]CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase [clinicaltrials:NCT00084916]clinicaltrials:NCT00085384CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia [clinicaltrials:NCT00086840]Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia [clinicaltrials:NCT00087204]
location [clinicaltrials_vocabulary:location]
M D Anderson Cancer Center [clinicaltrials_resource:c3b39bc43c0411fc92a031d9d271ce71]
Bio2RDF identifier
c3b39bc43c0411fc92a031d9d271ce71
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:c3b39bc43c0411fc92a031d9d271ce71
address [clinicaltrials_vocabulary:address]
identifier
clinicaltrials_resource:c3b39bc43c0411fc92a031d9d271ce71
title
M D Anderson Cancer Center
@en
type
label
M D Anderson Cancer Center [clinicaltrials_resource:c3b39bc43c0411fc92a031d9d271ce71]
@en